# The Weight Comparison Used 257 People

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/the-weight-comparison-used-257-people

> A 30,458-patient study reported surgery producing 28.3% weight loss against 10.3% on GLP-1s, at lower two-year cost. The cost half uses the whole cohort. The weight half uses 1.6% of one arm.

## Key points

- The 28.3% vs 10.3% weight comparison used 257 of 16,357 drug patients.
- Weight is in the record only for people who got weighed. Surgical follow-up guarantees it; prescriptions do not.
- The 'GLP-1' arm pools six drugs differing threefold in effect.
- The cost finding IS solid: $63,483 vs $51,794 over two years, on the full cohort.
- Two years is the friendliest window for surgery, because its costs are front-loaded.
- An author declares fees from Medtronic, a surgical device maker.

A study of 30,458 patients reported that bariatric surgery produced 28.3% weight loss against 10.3% on GLP-1 medications, at lower two-year cost.[1] The cost half rests on the whole cohort and deserves to be taken seriously. The weight half rests on **257 of the 16,357 people in the drug arm**, and that is a different kind of number.

## What the study compared

Researchers linked an insurance claims database to a health system’s medical records and identified adults with class II or III obesity who had either metabolic bariatric surgery (sleeve gastrectomy or gastric bypass) or a GLP-1 prescription. Propensity score weighting balanced the groups on prior spending, health care use, age, sex, comorbidities and smoking. The result was 14,101 surgical patients and 16,357 on medication, followed for a little under three years on average.

*What each finding was based on.[1]*

| Finding | Result | Sample used |
| --- | --- | --- |
| Total cost over 2 years | $63,483 (GLP-1) vs $51,794 (surgery) | **The full cohort, 30,458** |
| Total weight loss | 10.3% (GLP-1) vs 28.3% (surgery) | **257 and 1,291** |

## Who those 257 people are

> **Weight appears in the analysis only for patients whose weights were recorded in that health system’s medical records: 1.6% of the drug arm and 9.2% of the surgical arm.** Those are not random samples. A surgical patient has scheduled follow-up appointments where they are weighed as a matter of protocol. Someone filling a GLP-1 prescription may have no recorded weight in that system at all, and the ones who do are those with a particular pattern of engagement with that particular network.

Which direction that biases the result cannot be known from the outside, and that is the problem. The more than 98% of the drug arm whose weights are missing could be doing better than the 257 or worse. What can be said is that a comparison built on 1.6% of one arm and 9.2% of the other is not the comparison the propensity weighting was designed to protect, because the weighting balanced the full cohort and not these two fragments.

> The careful matching was done on 30,458 people. The headline number was computed on 1,548 of them.

## And the drug arm is not one drug

The GLP-1 group pooled dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide and tirzepatide. Those agents differ enormously in what they do to weight. The older ones, such as [exenatide](https://glpwatchdog.org/research/exenatide-byetta-bydureon-weight-loss), were never marketed for weight loss and produce a fraction of the effect of the newest two.

So 10.3% is an average across a class whose members are not interchangeable, in a period during which prescribing shifted heavily toward the strongest agents. It is a fair description of “people who took some GLP-1 during these years.” It is not a fair description of what someone starting tirzepatide today should expect, and the figure will be quoted as though it were.

## The cost finding is the solid half

Two-year costs came to $63,483 for the medication group against $51,794 for surgery, with the difference driven by pharmacy spending that stayed higher throughout the second year. That analysis used the entire cohort, the difference is large, and it makes an obvious point: an operation is paid for once, and a prescription is paid for every month for as long as it works.

> **Two years is also the most favorable window surgery could be given.** Surgical costs and surgical risks are concentrated at the start, then largely stop. Drug costs keep accumulating. Extend the window and the gap widens; shorten it below the surgical episode and it reverses. The choice of window is doing real work in that comparison, and it is a defensible choice rather than a hidden one.

The authors conclude by asking whether surgery should still be treated as a last resort. That is a reasonable question and the cost data support raising it. What the cost data cannot address is the thing that makes surgery a last resort for most people: it is irreversible, it carries operative risk, and it changes how someone eats permanently. Those are not costs and do not appear in a claims database.

Among the authors’ declared interests are personal fees from Medtronic, a manufacturer of surgical devices, alongside Novo Nordisk and Eli Lilly. That is disclosed in the paper, it is unremarkable in this field, and it is context for a conclusion favoring surgery.

## What to take from it

- **Surgery produces more weight loss than these drugs.** That is established elsewhere by better evidence; we cover a cleaner head-to-head in [surgery versus GLP-1 drugs](https://glpwatchdog.org/research/surgery-versus-glp1-drugs). Nothing here is surprising, and this study’s particular weight numbers are weakly supported.
- **The ongoing cost difference is real** and is the study’s useful contribution.
- **Do not carry the 10.3% anywhere.** It averages six drugs of very different potency, measured in 1.6% of the people taking them.
- **The decision is not primarily arithmetic.** Irreversibility, operative risk and permanent changes to eating are the substance of it.

## Frequently asked questions

### Does bariatric surgery beat GLP-1 drugs for weight loss?

It produces more weight loss, which is well established. This study reported 28.3% against 10.3%, but that comparison used weight data from only 257 of 16,357 patients in the drug arm and 1,291 of 14,101 in the surgical arm.

### Why does the small sample matter so much?

Weight was available only for patients whose weights were recorded in one health system's records. Surgical patients are weighed at protocol follow-ups; medication patients often are not. The careful statistical matching was done on all 30,458 people, while the headline was computed on 1,548 of them.

### Is 10.3% what I should expect on a GLP-1?

No. That figure averages six different drugs, including older ones never marketed for weight loss that produce a fraction of the effect of semaglutide or tirzepatide.

### Is surgery cheaper?

Over the two years studied, yes. Surgery cost $51,794 against $63,483 for medication, because an operation is paid for once and a prescription is paid for continuously. That analysis used the full cohort and is the study's strongest finding.

### Should surgery be considered earlier then?

The authors raise that question and the cost data support raising it. Cost is not what makes surgery a last resort, though. Irreversibility, operative risk and permanent changes to how someone eats are, and none of those appear in a claims database.

## References

1. Barrett TS, Hafermann JO, Richards S, et al. Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. JAMA Surgery. 2025. PMID: 40960852. https://pubmed.ncbi.nlm.nih.gov/40960852/

---

Cite as: GLP Watchdog, Nora Bissett, "The Weight Comparison Used 257 People", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/the-weight-comparison-used-257-people

Canonical HTML page: https://glpwatchdog.org/research/the-weight-comparison-used-257-people

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
